David Cutler, MD, FRCP(C)
David Cutler is a dynamic clinical researcher with over 30 years of experience as a leader in translational pharmacology at large and small pharmaceutical companies. He led numerous early development teams driving innovative, efficient strategies to rapidly transition candidates through first introduction into humans to proof-of-concept, dose selection, and risk mitigation leading to multiple successful US and global regulatory approvals. David has designed and spearheaded programs in oncologic and non-oncologic indications for diverse candidates including small molecules, monoclonal antibodies, bioconjugates, gene therapies, CAR T-cells and CAR iNKT-cells. Integrating the expertise of individual team members in pharmacokinetics, pharmacodynamics, molecular biomarker identification, pharmacogenomics and modeling/simulation, the programs were designed to assure that patients receive the dosage that maximizes therapeutic efficacy and optimizes patient safety. During his 25 year tenure at Schering-Plough/Merck, he held positions of increasing responsibility and retired as Distinguished Clinical Fellow in Clinical Research. Subsequently, he was Senior Vice-President and Deputy CMO at Athenex, Inc, where he oversaw Phase 1 to 3 studies in Oncology and Dermatology and Phase 1 studies in cellular immunotherapy of cancer. David consults with clients to design and implement early clinical research programs through proof-of-concept as well as supporting ancillary studies required for regulatory submissions.
David received his MD degree from the University of Saskatchewan, with subsequent training and research in Internal Medicine and Endocrinology and Metabolism at the Mayo Clinic, University of Toronto, and University of California, San Diego.
David received his MD degree from the University of Saskatchewan, with subsequent training and research in Internal Medicine and Endocrinology and Metabolism at the Mayo Clinic, University of Toronto, and University of California, San Diego.